This document is an excerpt from the EUR-Lex website
It strengthens the role of the European Medicines Agency (EMA) in crisis preparedness and the management of medicinal products and medical devices, allowing the EMA to closely monitor and mitigate shortages of medicines and facilitate the faster approval of medicines that could treat or prevent a disease causing a public health crisis. After an initial transition period, the EMA will also coordinate responses of European Union (EU) Member States on shortages of critical medical devices in the event of a crisis.
Sponsors of clinical trials have to publish the trial protocol and a summary of the results. In the event of marketing authorisation, the EMA publishes product information including conditions of use.
It has applied since , except for the rules on shortages of critical medical devices, which will apply from .
For further information, see:
Regulation (EU) 2022/123 of the European Parliament and of the Council of on a reinforced role for the European Medicines Agency in crisis preparedness and management for medicinal products and medical devices (OJ L 20, , pp. 1–37).
last update